Human Immunoglobulins
Guillain-Barre Syndrome
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Emory University
Modality
other_biological
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00004833CT.gov Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Guillain-Barre Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Immunoglobulins (this asset) | Emory University | N/A | D · 30 |
| Furfat | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purinf | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purclo | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purphl | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Smoliv | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purapo | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purwet | All Natural Medicine Clinic, LLC | P1/2 | CCC |
Other indications for Human Immunoglobulins
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P3 | BB · 70 |
| Epilepsy | — | P4 | BB · 66 |
| Plasma Cell Myeloma | — | P2/3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Human Immunoglobulins in Guillain-Barre Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/human-immunoglobulins-guillain-barre-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →